Drug industry spends nearly $50 million to fight drug-price referendum; Novartis weighs sales of generic unit; ICER to evaluate all newly approved drugs
Merck CEO Kenneth Frazier's exit from a presidential manufacturing council may go down as one of the most principled stands by the CEO of a major U.S. company, let alone a drugmaker.
It's not often that pharmaceutical companies are held up as examples of morality or leadership to the general public.
The FDA to study whether linking to risk information affects patient recall; patients view docs who take industry payments as less honest; Mallinckrodt ups political donations
How Huge and the New York Civil Liberties Union used lawmakers' own antiquated ideas to support the Reproductive Health Act.